According to an examination by Reuters, “Johnson & Johnson knew for decades that asbestos exists in its baby powder. Almost 11,700 plaintiffs in a lawsuit against the company including thousands of women having ovarian cancer alleged that the company’s talc leads to their illness. The examination relied upon depositions, trial testimony, and “internal reports, company memos, and other confidential documents.”
Reuters stated that from 1971 to 2000, the company’s raw talc and finished powders frequently tested positive for little amounts of asbestos. On that, the company executives, scientists, mine managers, lawyers, and doctors worried about the problem and how to deal with it while failing to reveal it to the public or regulators. As per the reports, the documents also portray successful attempts to control the U.S. regulators’ plans to restrict asbestos in beauty talc products and scientific investigation on the health effects of talc. There are no safe levels of disclosure to asbestos, according to the WHO (World Health Organization) and even the small amounts are dangerous. That asbestos is the prime cause of mesothelioma and has been extensively known since early 1970. Reportedly, Johnson & Johnson’s shares decline by 10% in recent time.
Recently, Johnson & Johnson’s was also in the news as its Tremfya surpassed Novartis’ best-seller Cosentyx in one-on-one psoriasis clash. Johnson & Johnson’s Tremfya might have made its entry after chief rivals, but it made its mark lately in the next-generation psoriasis field with Cosentyx-topping one-on-one data. At the 48-Week mark, almost 84.5% of Tremfya patients in a Phase III trial gained a score of 90 on the PASI (Psoriasis Area Severity Index)—which is a normally used metric for calculating a response to psoriasis drugs—and merely 70% of individuals having the Cosentyx could say the same.